Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for triptorelin, the scientific conclusions are as follows:

In view of available data on idiopathic intracranial hypertension from the literature, spontaneous reports including in some cases a close temporal relationship and a positive de-challenge the PRAC considers a causal relationship between triptorelin and idiopathic intracranial hypertension is at least a reasonable possibility. The PRAC concluded that the product information of products containing triptorelin indicated for the treatment of children should be amended accordingly.

In view of available data on fatty liver from the literature and non-clinical data the PRAC considers a causal relationship between triptorelin and fatty liver is at least a reasonable possibility. The PRAC concluded that the product information of products containing triptorelin indicated for the treatment of male patients should be amended accordingly.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for triptorelin the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing triptorelin is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing triptorelin are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.4

Products indicated in children

A warning should be added as follows:

Idiopathic intracranial hypertension

Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in paediatric patients receiving triptorelin. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, vision disturbances and tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of triptorelin should be considered.

Products indicated in males

[…] In addition, from epidemiological data, it has been observed that patients may experience metabolic changes (e.g. glucose intolerance**, fatty liver**) and an increased risk of cardiovascular disease during androgen deprivation therapy. However, prospective data did not confirm the link between treatment with GnRH analogues and an increase in cardiovascular mortality. Patients at high risk for metabolic or cardiovascular diseases should be carefully assessed before commencing treatment and during androgen deprivation therapy.

- Section 4.8

Products indicated in children

The following adverse reaction should be added under the SOC Nervous system disorders with a frequency unknown:

Idiopathic intracranial hypertension (pseudotumor cerebri) (see section 4.4)

Package Leaflet

Products indicated in children

Section 2:

Warnings and precautions

Talk to your doctor:

If your child suffers from a bad or recurrent headache, problems with eyesight and ringing or buzzing in the ears, contact a doctor immediately (see section 4).

Section 4: Possible side effects

Not known: frequency cannot be estimated from the available data

Idiopathic intracranial hypertension (increased intracranial pressure around the brain characterised by headache, double vision and other visual symptoms, and ringing or buzzing in the ears)

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	December CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	30 January 2023
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	30 March 2023